News Center

Home page

Peak Report

News reports

The company held the 7th meeting of the 11th board of directors and the 7th meeting of the 10th board of supervisors to review and approve the annual work report and other related proposals

Release time:

2022-05-05

News from our newspaper # February 16 , Chairman Jiang Xiaomeng of the Group Company presided over the meeting of the 11th Board of Directors of the Company, it reviewed and approved 17 related reports and proposals such as 2021 annual board of directors report, 2021 annual general manager business report, 2021 annual report, 2021 annual financial final accounts report, 2021 annual profit distribution plan, etc.

General Manager's report pointed out that 2021 is the first year of the national "14th Five-Year Plan" , The management team, according to the company's five-year development plan and the annual management plan approved by the board of directors, focuses on the general working policy of "following the rules, keeping the right and bringing forth new ideas, reforming and innovating, and continuously improving, calmly deal with the new coronary pneumonia epidemic, raw material prices ups and downs, production restrictions and power restrictions and many other challenges, better to complete the work objectives set at the beginning of the year. As of the end of 2021 , the company's total assets were 70.24 .9 billion yuan, up 10.74% year-on-year, and the net assets attributable to shareholders of listed companies were 52.07 .3 billion yuan, up 17.39% year-on-year. For the whole year, operating income reached 38.05 .7 billion yuan, up 17.17% year-on-year, net profit attributable to shareholders reached 9.24 .1 billion yuan, up 58.12% year-on-year, and operating performance reached the best level in history.

2021

, the company's cement plate industry chain extension war made new progress, holding the establishment of Hubei peak new building materials Co., Ltd., orderly promote the mechanism of sand project. Actively participated in the major asset restructuring of Tianshan shares and achieved good investment returns. All cement enterprises under the company continue to implement benchmarking management and fine management, carry out in-depth "three reductions and three improvements" activities, steadily implement various technological transformation work, strictly control production costs, and continuously improve the operation efficiency of enterprises. A total of cement clinker ,675 tons were sold throughout the year, up 28% year on year. Daye Peak manages the procurement of raw materials through multi-channel, open and transparent, and full supervision, and strictly controls the procurement cost while ensuring the quality. Continuously optimize the batching scheme, complete the technical transformation of the automatic batching system, increase the proportion of limestone in raw materials, and reduce the cost of raw materials; Continuously optimize the process parameters and use the MES system to trace the optimal parameters, combined with the implementation of more than ten technical transformations such as low-nitrogen combustion at the kiln end and dust collection system at the kiln end, the stability of the equipment has been improved, the overall production capacity of the kiln system has been improved, and the annual cement output has reached the best level in history. Yunnan Jianfeng strictly controls the procurement cost of raw materials by strengthening bidding management. Through the technical renovation of grate cooler, preheater and other equipment, the output of rotary kiln has been effectively increased. Affected by the completion of some key projects in the region and the commissioning of new cement production capacity, the competition in the cement market in this region has intensified and the price has dropped greatly. Therefore, the company further strengthened the regional market segmentation work according to market changes in time and formulated differentiated marketing strategies for different market segments, basically maintain the balance of production and sales. 2021 is the first complete year after Guizhou Jianfeng was put into production. Guizhou Jianfeng relies on the advanced second-generation new dry-process cement production line and adopts digital intelligent control technology to realize all-round intelligent management such as safe production, product quality, material consumption and energy consumption. Strengthen operator training, improve skill level, timely adjust and optimize process parameters, and ensure product quality stability; The whole line has reached the standard and reached the production capacity, coal consumption, electricity consumption, operation rate, kiln production, labor productivity and other indicators reached a good level.

2021

, the company made progress in a number of technological innovations and engineering constructions in the pharmaceutical sector. The construction of the annual production of 20 .9 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical Co., Ltd. is progressing in an orderly manner. At present, the civil engineering and equipment installation and commissioning of the project have been basically completed, and the preliminary preparations for project acceptance and application for certification of cGMP are underway; new North Card and Peak North Card continue to implement comprehensive technological transformation, and intend to upgrade on the basis of existing pesticides and pharmaceutical intermediates, build a comprehensive research and development and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations in the pharmaceutical sector of the company. Jianfeng Pharmaceutical and its subsidiaries further increased their investment in research and development and completed the registration of moxifloxacin hydrochloride eye drops, lenvatinib mesylate capsules, valsartan amlodipine tablets and esomeprazole magnesium enteric-coated dry suspension 4 drugs. Peak pharmaceutical products won the bid for the first time in the national drug centralized procurement, olopatadine hydrochloride eye drops won the bid for the fourth batch of national drug centralized procurement, which is conducive to the market promotion of the product, sales have been greatly improved.

In addition, Jianfeng Health has completed the research and development of health food such as coenzyme Q10 soft capsule and broken ganoderma lucidum spore powder, and has obtained the record. Completed the development of many functional foods such as vitality V5 liquid drink and collagen liquid drink, and has now listed 6 ; "Development and Industrialization of Wall-broken Ganoderma lucidum Spore Powder for Enhancing Immunity" was approved by Jinhua Municipal Technology Innovation Project in 2021 . "Cranberry Extract" won the project of key high-tech products in Zhejiang Province in 2021 . Peak cable carried out the subway communication cable "Zhejiang manufacturing" standard construction work, high-speed data transmission with twisted pair communication cable through the "Zhejiang manufacturing" certification, won the representative of Zhejiang manufacturing benchmark "word mark". According to the development trend of regional trade and logistics, combined with the characteristics of the enterprise itself, Jianfeng International Trade has continuously improved its business development model and promoted the development of modern warehousing logistics, commodity supply chain and network freight platform business in an orderly manner. On the day of

, the company also held the st meeting of the 10th board of supervisors, deliberating and passing related reports and proposals such as the company's 2021 annual board of supervisors report. (remaining fruit)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页